Trial Profile

Phase 1 Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

18 Nov 2024 Planned End Date changed from 1 May 2026 to 1 Oct 2025.
18 Nov 2024 Planned primary completion date changed from 1 May 2025 to 1 Oct 2025.
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com